{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:47:22Z","timestamp":1790261242835,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venezuelan equine encephalitis virus (VEEV) is a mosquito borne alphavirus which leads to high viremia in equines followed by lethal encephalitis and lateral spread to humans. In addition to naturally occurring outbreaks, VEEV is a potential biothreat agent with no approved human vaccine or therapeutic currently available. Single domain antibodies (sdAb), also known as nanobodies, have the potential to be effective therapeutic agents. Using an immune phage display library derived from a llama immunized with an equine vaccine that included inactivated VEEV, five sdAb sequence families were identified that showed varying ability to neutralize VEEV. One of the sequence families had been identified previously in selections against chikungunya virus, a related alphavirus of public health concern. A key advantage of sdAb is the ability to optimize properties such as neutralization capacity through protein engineering. Neutralization of VEEV was improved by two orders of magnitude by genetically linking sdAb. One of the bivalent constructs showed effective neutralization of both VEEV and chikungunya virus. Several of the bivalent constructs neutralized VEEV in cell-based assays with reductions in the number of plaques by 50% at protein concentrations of 1\u00a0ng\/mL or lower, making future evaluation of their therapeutic potential compelling.<\/jats:p>","DOI":"10.1038\/s41598-021-04434-x","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T06:03:33Z","timestamp":1642053813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis"],"prefix":"10.1038","volume":"12","author":[{"given":"Jinny L.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zabetakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Shriver-Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Weger-Lucarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen R.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"issue":"1","key":"4434_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","volume":"49","author":"SC Weaver","year":"2004","unstructured":"Weaver, S. C., Ferro, C., Barrera, R., Boshell, J. & Navarro, J.-C. Venezuelan equine encephalitis. Annu. Rev. Entomol. 49(1), 141\u2013174. https:\/\/doi.org\/10.1146\/annurev.ento.49.061802.123422 (2004).","journal-title":"Annu. Rev. Entomol."},{"issue":"5","key":"4434_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jama.1997.03550050061035","volume":"278","author":"DR Franz","year":"1997","unstructured":"Franz, D. R. et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278(5), 399\u2013411. https:\/\/doi.org\/10.1001\/jama.1997.03550050061035 (1997).","journal-title":"JAMA"},{"issue":"2","key":"4434_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/v11020164","volume":"11","author":"A Sharma","year":"2019","unstructured":"Sharma, A. & Knollmann-Ritschel, B. Current understanding of the molecular basis of Venezuelan equine encephalitis virus pathogenesis and vaccine development. Viruses 11(2), 164. https:\/\/doi.org\/10.3390\/v11020164 (2019).","journal-title":"Viruses"},{"issue":"4","key":"4434_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","volume":"14","author":"PR Pittman","year":"1996","unstructured":"Pittman, P. R. et al. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 14(4), 337\u2013343. https:\/\/doi.org\/10.1016\/0264-410X(95)00168-Z (1996).","journal-title":"Vaccine."},{"issue":"2","key":"4434_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.virol.2012.01.038","volume":"426","author":"LM O'Brien","year":"2012","unstructured":"O\u2019Brien, L. M., Goodchild, S. A., Phillpotts, R. J. & Perkins, S. D. A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48h after airborne challenge. Virology 426(2), 100\u2013105. https:\/\/doi.org\/10.1016\/j.virol.2012.01.038 (2012).","journal-title":"Virology"},{"issue":"1","key":"4434_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.virusres.2006.02.003","volume":"120","author":"RJ Phillpotts","year":"2006","unstructured":"Phillpotts, R. J. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res. 120(1), 107\u2013112. https:\/\/doi.org\/10.1016\/j.virusres.2006.02.003 (2006).","journal-title":"Virus Res."},{"issue":"12","key":"4434_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008157","volume":"15","author":"CW Burke","year":"2019","unstructured":"Burke, C. W. et al. Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure. PLoS Pathog. 15(12), e1008157. https:\/\/doi.org\/10.1371\/journal.ppat.1008157 (2019).","journal-title":"PLoS Pathog."},{"issue":"82","key":"4434_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: Natural single-domain antibodies. Annu. Rev. Biochem. 82(82), 775\u2013797. https:\/\/doi.org\/10.1146\/annurev-biochem-063011-092449 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"4434_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2859-10-44","author":"A de Marco","year":"2011","unstructured":"de Marco, A. Biotechnological applications of recombinant single-domain antibody fragments. Microb. Cell Fact. https:\/\/doi.org\/10.1186\/1475-2859-10-44 (2011).","journal-title":"Microb. Cell Fact."},{"issue":"3","key":"4434_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","volume":"198","author":"J Wesolowski","year":"2009","unstructured":"Wesolowski, J. et al. Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198(3), 157\u2013174. https:\/\/doi.org\/10.1007\/s00430-009-0116-7 (2009).","journal-title":"Med. Microbiol. Immunol."},{"key":"4434_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00865","author":"ER Goldman","year":"2017","unstructured":"Goldman, E. R., Liu, J. L., Zabetakis, D. & Anderson, G. P. Enhancing stability of camelid and shark single domain antibodies: An overview. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.00865 (2017).","journal-title":"Front. Immunol."},{"issue":"7","key":"4434_CR12","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1021\/bc300066a","volume":"23","author":"Y Vugmeyster","year":"2012","unstructured":"Vugmeyster, Y. et al. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol). Bioconjugate Chem. 23(7), 1452\u20131462. https:\/\/doi.org\/10.1021\/bc300066a (2012).","journal-title":"Bioconjugate Chem."},{"issue":"3","key":"4434_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/antib4030141","volume":"4","author":"S Hoefman","year":"2015","unstructured":"Hoefman, S., Ottevaere, I., Baumeister, J. & Sargentini-Maier, M. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies\u00ae. Antibodies 4(3), 141. https:\/\/doi.org\/10.3390\/antib4030141 (2015).","journal-title":"Antibodies"},{"issue":"1","key":"4434_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jov\u010devska","year":"2020","unstructured":"Jov\u010devska, I. & Muyldermans, S. The therapeutic potential of nanobodies. BioDrugs 34(1), 11\u201326. https:\/\/doi.org\/10.1007\/s40259-019-00392-z (2020).","journal-title":"BioDrugs"},{"issue":"3","key":"4434_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.antiviral.2011.09.002","volume":"92","author":"P Vanlandschoot","year":"2011","unstructured":"Vanlandschoot, P. et al. Nanobodies\u00ae: New ammunition to battle viruses. Antiviral Res. 92(3), 389\u2013407. https:\/\/doi.org\/10.1016\/j.antiviral.2011.09.002 (2011).","journal-title":"Antiviral Res."},{"key":"4434_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01802","author":"Y Wu","year":"2017","unstructured":"Wu, Y., Jiang, S. & Ying, T. Single-domain antibodies as therapeutics against human viral diseases. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.01802 (2017).","journal-title":"Front. Immunol."},{"key":"4434_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.molimm.2018.11.016","volume":"105","author":"JL Liu","year":"2019","unstructured":"Liu, J. L., Shriver-Lake, L. C., Zabetakis, D., Anderson, G. P. & Goldman, E. R. Selection and characterization of protective anti-chikungunya virus single domain antibodies. Mol. Immunol. 105, 190\u2013197. https:\/\/doi.org\/10.1016\/j.molimm.2018.11.016 (2019).","journal-title":"Mol. Immunol."},{"issue":"2","key":"4434_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1128\/jvi.00461-12","volume":"87","author":"J Matz","year":"2013","unstructured":"Matz, J. et al. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J. Virol. 87(2), 1137\u20131149. https:\/\/doi.org\/10.1128\/jvi.00461-12 (2013).","journal-title":"J. Virol."},{"issue":"4","key":"4434_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017665","volume":"6","author":"A Hultberg","year":"2011","unstructured":"Hultberg, A. et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS ONE 6(4), e17665. https:\/\/doi.org\/10.1371\/journal.pone.0017665 (2011).","journal-title":"PLoS ONE"},{"issue":"5","key":"4434_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2018.1470727","volume":"10","author":"A Larios Mora","year":"2018","unstructured":"Larios Mora, A. et al. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. MAbs 10(5), 778\u2013795. https:\/\/doi.org\/10.1080\/19420862.2018.1470727 (2018).","journal-title":"MAbs"},{"issue":"1","key":"4434_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jneuroim.2009.08.005","volume":"215","author":"E Furrer","year":"2009","unstructured":"Furrer, E., Hulmann, V. & Urech, D. M. Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J. Neuroimmunol. 215(1), 65\u201372. https:\/\/doi.org\/10.1016\/j.jneuroim.2009.08.005 (2009).","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"4434_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/jnc.14332","volume":"145","author":"JR Gomes","year":"2018","unstructured":"Gomes, J. R. et al. Delivery of an anti-transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons. J Neurochem. 145(5), 393\u2013408. https:\/\/doi.org\/10.1111\/jnc.14332 (2018).","journal-title":"J Neurochem."},{"key":"4434_CR23","doi-asserted-by":"publisher","first-page":"8245","DOI":"10.1021\/ac0610053","volume":"78","author":"ER Goldman","year":"2006","unstructured":"Goldman, E. R. et al. Facile generation of a heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal. Chem. 78, 8245\u20138255 (2006).","journal-title":"Anal. Chem."},{"key":"4434_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antib7040044","author":"JL Liu","year":"2018","unstructured":"Liu, J. L., Shriver-Lake, L. C., Zabetakis, D., Goldman, E. R. & Anderson, G. P. Selection of single-domain antibodies towards western equine encephalitis virus. Antibodies (Basel, Switzerland) https:\/\/doi.org\/10.3390\/antib7040044 (2018).","journal-title":"Antibodies (Basel, Switzerland)"},{"issue":"22","key":"4434_CR25","doi-asserted-by":"publisher","first-page":"10881","DOI":"10.1093\/nar\/16.22.10881","volume":"16","author":"F Corpet","year":"1988","unstructured":"Corpet, F. Multiple sequence alignment with hierarchical-clustering. Nucleic Acids Res. 16(22), 10881\u201310890. https:\/\/doi.org\/10.1093\/nar\/16.22.10881 (1988).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"4434_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/bioinformatics\/btv552","volume":"32","author":"J Dunbar","year":"2015","unstructured":"Dunbar, J. & Deane, C. M. ANARCI: Antigen receptor numbering and receptor classification. Bioinformatics 32(2), 298\u2013300. https:\/\/doi.org\/10.1093\/bioinformatics\/btv552 (2015).","journal-title":"Bioinformatics"},{"issue":"1","key":"4434_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0145-305X(02)00039-3","volume":"27","author":"M-P Lefranc","year":"2003","unstructured":"Lefranc, M.-P. et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 27(1), 55\u201377. https:\/\/doi.org\/10.1016\/S0145-305X(02)00039-3 (2003).","journal-title":"Dev. Comp. Immunol."},{"issue":"9","key":"4434_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106263","volume":"9","author":"SA Walper","year":"2014","unstructured":"Walper, S. A., Liu, J. L., Zabetakis, D., Anderson, G. P. & Goldman, E. R. Development and evaluation of single domain antibodies for vaccinia and the L1 antigen. PLoS ONE 9(9), e106263. https:\/\/doi.org\/10.1371\/journal.pone.0106263 (2014).","journal-title":"PLoS ONE"},{"issue":"Supplement C","key":"4434_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.toxicon.2017.06.002","volume":"135","author":"LC Shriver-Lake","year":"2017","unstructured":"Shriver-Lake, L. C., Zabetakis, D., Goldman, E. R. & Anderson, G. P. Evaluation of anti-botulinum neurotoxin single domain antibodies with additional optimization for improved production and stability. Toxicon 135(Supplement C), 51\u201358. https:\/\/doi.org\/10.1016\/j.toxicon.2017.06.002 (2017).","journal-title":"Toxicon"},{"issue":"1","key":"4434_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/bios2010043","volume":"2","author":"RH Glaven","year":"2012","unstructured":"Glaven, R. H. et al. Linking single domain antibodies that recognize different epitopes on the same target. Biosensors 2(1), 43. https:\/\/doi.org\/10.3390\/bios2010043 (2012).","journal-title":"Biosensors"},{"key":"4434_CR31","doi-asserted-by":"publisher","first-page":"561530","DOI":"10.3389\/fmicb.2020.561530","volume":"11","author":"V Raabe","year":"2020","unstructured":"Raabe, V. et al. The immune response to eastern equine encephalitis virus acquired through organ transplantation. Front Microbiol. 11, 561530. https:\/\/doi.org\/10.3389\/fmicb.2020.561530 (2020).","journal-title":"Front Microbiol."},{"issue":"8","key":"4434_CR32","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1099\/vir.0.008656-0","volume":"90","author":"CH Logue","year":"2009","unstructured":"Logue, C. H. et al. Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model. J. Gen. Virol. 90(8), 1848\u20131858. https:\/\/doi.org\/10.1099\/vir.0.008656-0 (2009).","journal-title":"J. Gen. Virol."},{"key":"4434_CR33","doi-asserted-by":"publisher","first-page":"626028","DOI":"10.3389\/fmed.2021.626028","volume":"8","author":"JL Liu","year":"2021","unstructured":"Liu, J. L. et al. Stabilization of a broadly neutralizing anti-chikungunya virus single domain antibody. Front. Med. Lausanne. 8, 626028. https:\/\/doi.org\/10.3389\/fmed.2021.626028 (2021).","journal-title":"Front. Med. Lausanne."},{"key":"4434_CR34","doi-asserted-by":"publisher","first-page":"e52716","DOI":"10.7554\/eLife.52716","volume":"9","author":"PJ Wichgers Schreur","year":"2020","unstructured":"Wichgers Schreur, P. J. et al. Multimeric single-domain antibody complexes protect against bunyavirus infections. Elife 9, e52716. https:\/\/doi.org\/10.7554\/eLife.52716 (2020).","journal-title":"Elife"},{"key":"4434_CR35","doi-asserted-by":"publisher","unstructured":"Hanke, L. et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat. Commun. 11(1), 4420. https:\/\/doi.org\/10.1038\/s41467-020-18174-5 (2020).","DOI":"10.1038\/s41467-020-18174-5"},{"key":"4434_CR36","unstructured":"Griffin DF. Alphaviruses. Fields Virology: Sixth Edition. 1: Wolters Kluwer Health Adis (ESP); 2013."},{"issue":"21","key":"4434_CR37","doi-asserted-by":"publisher","first-page":"10118","DOI":"10.1128\/JVI.75.21.10118-10131.2001","volume":"75","author":"M Powers Ann","year":"2001","unstructured":"Powers Ann, M. et al. Evolutionary Relationships and Systematics of the Alphaviruses. J Virol. 75(21), 10118\u201310131. https:\/\/doi.org\/10.1128\/JVI.75.21.10118-10131.2001 (2001).","journal-title":"J Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04434-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04434-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04434-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:04:39Z","timestamp":1669305879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04434-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04434-x","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/HF6VEE","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JL, GA, DZ and EG are inventors on a provisional U.S. patent application (serial no. 63224642) filed July 22, 2021. Single Domain Antibodies that Bind and Neutralize Venezuelan Equine Encephalitis Virus. The remaining authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"700"}}